Drug development represents a highly complex, inefficient and costly process. Over the past decade, the widespread use of nuclear imaging, owing to its functional and molecular nature, has proven to be a determinant in improving the efficiency in selecting the candidate drugs that should either be abandoned or moved forward into clinical trials. This helps not only with the development of safer and effective drugs but also with the shortening of time-to-market. The modern concept and future trends concerning molecular imaging will assumedly be hybrid or multimodality imaging, including combinations between high sensitivity and functional (molecular) modalities with high spatial resolution and morphological techniques.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drudis.2014.01.003 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!